Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe |
NCT02053116: A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin |
|
|
| Terminated | 2a | 8 | US | PF-05175157, Placebo | Pfizer | Type 2 Diabetes Mellitus | 04/14 | 04/14 | | |
NCT00650806: A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes |
|
|
| Completed | 2 | 376 | US | Canagliflozin (JNJ-28431754), Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Obesity | 09/08 | 09/08 | | |
|
NCT00642278: An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes |
|
|
| Completed | 2 | 451 | US, Canada, Europe, RoW | Canagliflozin (JNJ-28431754), JNJ-28431754, Sitagliptin, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent | 01/09 | 01/09 | | |
|
NCT01022112: An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes |
|
|
| Completed | 2 | 383 | Japan | TA-7284-Low, TA-7284-Low-middle, TA-7284-High-middle, TA-7284-High, Placebo | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 09/10 | 09/10 | | |
|
NCT01340664 / 2010-024256-28: An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy |
|
|
| Completed | 2 | 279 | US, Canada, Europe, RoW | Canagliflozin 50 mg, Placebo, Canagliflozin 150 mg, Metformin | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 04/12 | 04/12 | | |
NCT02139943: A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM) |
|
|
| Completed | 2 | 352 | US, Canada | Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Janssen Research & Development, LLC | Diabetes Mellitus, Type 1 | 06/15 | 06/15 | | |
NCT00707954: Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients |
|
|
| Completed | 1/2 | 61 | Japan | TA-7284, Placebo of TA-7284 | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 02/09 | 02/09 | | |